CA2869280C - Traitements ophtalmiques - Google Patents

Traitements ophtalmiques Download PDF

Info

Publication number
CA2869280C
CA2869280C CA2869280A CA2869280A CA2869280C CA 2869280 C CA2869280 C CA 2869280C CA 2869280 A CA2869280 A CA 2869280A CA 2869280 A CA2869280 A CA 2869280A CA 2869280 C CA2869280 C CA 2869280C
Authority
CA
Canada
Prior art keywords
eye
composition
aqueous composition
tramadol
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2869280A
Other languages
English (en)
Other versions
CA2869280A1 (fr
Inventor
Anant Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optosolve Research and Development Ltd
Original Assignee
Optosolve Research and Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105732.0A external-priority patent/GB201105732D0/en
Priority claimed from GBGB1105731.2A external-priority patent/GB201105731D0/en
Application filed by Optosolve Research and Development Ltd filed Critical Optosolve Research and Development Ltd
Publication of CA2869280A1 publication Critical patent/CA2869280A1/fr
Application granted granted Critical
Publication of CA2869280C publication Critical patent/CA2869280C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions aqueuses appropriées pour une administration topique à l'il humain ou animal, contenant au moins un lubrifiant ophtalmique polymère soluble dans l'eau, tel que le hyaluronate, un gel de carbomère ou l'hypromellose, conjointement avec un analgésique soluble dans l'eau. L'analgésique peut être un opioïde, en particulier un opioïde ayant une affinité pour les récepteurs 5-HT, tels que le tramadole. Des taux typiques de tramadol devraient se situer dans la plage allant de 0,5 % à 1,0 % p/v. Les compositions aqueuses peuvent, par exemple, être utilisées comme larmes artificielles et comme lubrifiants ophtalmiques généraux pour le traitement d'états tels que la sécheresse oculaire ou la blépharite. Des compositions supplémentaires combinent des agents actifs du point de vue ophtalmologique, tels que des produits pharmaceutiques, avec des opioïdes, tel que le tramadol, en particulier. Ces compositions peuvent être utilisées pour traiter l'il tout en réduisant la douleur ou l'inconfort qui serait normalement produit par l'administration de ces produits pharmaceutiques particuliers à l'il, et tout en augmentant l'efficacité des produits pharmaceutiques. L'invention concerne également des compositions, contenant des opioïdes ayant une activité de récepteur 5-H, qui sont d'utilité générale dans le soulagement de la douleur dans et autour de l'il.
CA2869280A 2011-04-05 2012-04-05 Traitements ophtalmiques Active CA2869280C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1105731.2 2011-04-05
GB1105732.0 2011-04-05
GBGB1105732.0A GB201105732D0 (en) 2011-04-05 2011-04-05 Ophthalmic lubricants
GBGB1105731.2A GB201105731D0 (en) 2011-04-05 2011-04-05 Topical analgesics
PCT/GB2012/000330 WO2012136969A2 (fr) 2011-04-05 2012-04-05 Traitements ophtalmiques

Publications (2)

Publication Number Publication Date
CA2869280A1 CA2869280A1 (fr) 2012-10-11
CA2869280C true CA2869280C (fr) 2020-03-10

Family

ID=46086008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2869280A Active CA2869280C (fr) 2011-04-05 2012-04-05 Traitements ophtalmiques

Country Status (12)

Country Link
US (2) US20140088199A1 (fr)
EP (2) EP3799866A1 (fr)
JP (2) JP6148664B2 (fr)
KR (2) KR102165246B1 (fr)
CN (2) CN103687594A (fr)
BR (1) BR112013025493A2 (fr)
CA (1) CA2869280C (fr)
ES (1) ES2836808T3 (fr)
HK (1) HK1254720A1 (fr)
MA (1) MA35070B1 (fr)
MX (1) MX346312B (fr)
WO (1) WO2012136969A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012136969A2 (fr) * 2011-04-05 2012-10-11 Anant Sharma Traitements ophtalmiques
GB201217522D0 (en) * 2012-10-01 2012-11-14 Sharma Anant ophthalmic therapy
GB2516138C (en) * 2013-04-09 2015-12-09 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
EP3091985B1 (fr) * 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandines pour leur utilisation topique dans le traitement des migraines.
WO2016172712A2 (fr) 2015-04-23 2016-10-27 Sydnexis, Inc. Composition ophtalmique
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016022066A1 (fr) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
MX2017010544A (es) * 2015-02-24 2018-06-18 Univ Illinois Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
EP3302426A4 (fr) 2015-05-29 2018-12-05 Sydnexis, Inc. Formulations pharmaceutiques stabilisées de d2o
ES2604816B1 (es) * 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
ES2871199T3 (es) * 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
CN108697665A (zh) * 2015-09-30 2018-10-23 乔治·爱德华·霍格 局部镇痛性疼痛缓解制剂、其制备和使用方法
CN105232449B (zh) * 2015-10-30 2019-04-09 上海昊海生物科技股份有限公司 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
WO2018071619A1 (fr) * 2016-10-12 2018-04-19 Ps Therapies Ltd Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation
WO2018212846A1 (fr) 2017-05-19 2018-11-22 Ocugen, Inc. Compositions ophtalmiques et leurs procédés d'utilisation
PL3634415T3 (pl) * 2017-06-08 2026-04-07 Eye Therapies, Llc Kompozycje okulistyczne zawierające brymonidynę i ketotifen do zastosowania w leczeniu alergii
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2018003456A (es) 2017-12-21 2019-09-06 Gruenenthal Gmbh Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
CN111886001A (zh) * 2018-03-13 2020-11-03 参天制药株式会社 滴眼型洗眼药用组合物
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
WO2021018750A1 (fr) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Compositions ophtalmiques comprenant des polymères viscosifiants et des acides nucléiques
US11504269B2 (en) 2019-11-19 2022-11-22 Jennifer L. Fabian Therapeutic bra
US20230077811A1 (en) * 2020-02-11 2023-03-16 Tufts Medical Center, Inc. Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
WO2021216909A1 (fr) * 2020-04-23 2021-10-28 Okogen, Inc. Traitement de conjonctivite virale
CN112007028A (zh) * 2020-09-03 2020-12-01 北京博纳致恒科技有限责任公司 一种复合睫状肌松弛剂的人工泪液及用途
WO2022183051A1 (fr) * 2021-02-26 2022-09-01 Vyluma Inc. Méthodes et formulations pour l'administration topique de gabapentinoïdes
WO2023285878A1 (fr) * 2021-07-13 2023-01-19 Aviation-Ophthalmology Procédés de détection, de traitement et de prévention de maladies, troubles et états oculaires induits par gpr68
WO2024010039A1 (fr) * 2022-07-06 2024-01-11 ロート製薬株式会社 Composition ophtalmologique
JPWO2024010045A1 (fr) * 2022-07-06 2024-01-11
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
JPWO2024010040A1 (fr) * 2022-07-06 2024-01-11
WO2025146828A1 (fr) * 2024-01-05 2025-07-10 ロート製薬株式会社 Composition ophtalmique
WO2025159099A1 (fr) * 2024-01-24 2025-07-31 国立大学法人北海道大学 Composition pharmaceutique, agent de traitement du blépharospasme, agent de traitement de l'hypersensibilité ou de la dystonie, et souris de modèle de symptômes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384043B1 (en) 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
ES2174337T3 (es) * 1996-12-16 2002-11-01 Alcon Lab Inc Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
JP2004143157A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 点眼剤
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
EP1611877A1 (fr) * 2004-06-28 2006-01-04 Universidade de Coimbra Méthodes pour la préparation d'articles ophthalmiques thérapeutiques à la libération prolongée en utilisant des fluides compressés pour l'imprégnation des medicaments
WO2007057508A2 (fr) 2005-11-18 2007-05-24 Orion Corporation Traitement de la douleur
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
WO2008153746A1 (fr) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations et procédés de traitement de l'œil sec
EP2311446A1 (fr) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprenant du Tramadol et du Célécoxib pour le traitement de la douleur
WO2012136969A2 (fr) * 2011-04-05 2012-10-11 Anant Sharma Traitements ophtalmiques

Also Published As

Publication number Publication date
JP6148664B2 (ja) 2017-06-14
EP3799866A1 (fr) 2021-04-07
JP6419876B2 (ja) 2018-11-07
BR112013025493A2 (pt) 2017-03-01
CA2869280A1 (fr) 2012-10-11
WO2012136969A3 (fr) 2013-01-03
US20160199320A1 (en) 2016-07-14
JP2014513073A (ja) 2014-05-29
US9913813B2 (en) 2018-03-13
CN107982211A (zh) 2018-05-04
MX2013011314A (es) 2014-03-27
MA35070B1 (fr) 2014-04-03
KR102165246B1 (ko) 2020-10-13
WO2012136969A2 (fr) 2012-10-11
JP2017141243A (ja) 2017-08-17
ES2836808T3 (es) 2021-06-28
KR20140145948A (ko) 2014-12-24
KR20190004815A (ko) 2019-01-14
MX346312B (es) 2017-03-15
HK1254720A1 (zh) 2019-07-26
EP2694048B1 (fr) 2020-10-07
EP2694048A2 (fr) 2014-02-12
US20140088199A1 (en) 2014-03-27
CN103687594A (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
US9913813B2 (en) Opthalmic treatments
CA2810537C (fr) Composition pour un liquide colloidal transparent ophtalmique topique qui subit une transition de phase liquide-gel dans l'ƒil
ES2812532T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir la rosácea
JP2014513073A5 (fr)
US20110294897A1 (en) Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
Bielory et al. Emerging therapeutics for ocular surface disease
WO2017042404A1 (fr) Composition pharmaceutique de tramadol destinée à un usage ophthalmique
So et al. Emerging trends in long-acting sustained drug delivery for glaucoma management
KR20200089703A (ko) 안구주위 분비선 또는 안구 표면에서의 이상 염증을 치료하기 위한 조성물 및 사용 방법
JP2004002358A (ja) 眼科用組成物
EP2979689A1 (fr) Composition pour gouttes ophtalmiques et système de distribution associé
Rathore et al. An overview and advancement in ocular drug delivery systems
CN115634226B (zh) 一种采用长春西汀治疗近视的方法
Williams et al. The birth of ocular pharmacology in the 20th century
Hughes et al. Ocular surface anatomy and physiology: impact on product development
KR20230098630A (ko) 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
Singh et al. Adverse effects of antiglaucoma medications: pathophysiology and novel drug delivery strategies for mitigation
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
US20230064711A1 (en) Compositions, kits and methods for enhancing therapeutic compliance

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170223

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251128